Provention Bio Inc. Stock News

The stock price of Provention Bio Inc (NASDAQ: PRVB) increased by 15.06% in the most recent trading session. This is why it happened.

NEW YORK , Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASTR, PRFX, VG, AFMD, and PRVB. Full story available on Benzinga.com

The FDA has approved Provention Bio Inc's (NASDAQ: PRVB) proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab PK/PD substudy. Related

Zacks Investment Research upgraded shares of Provention Bio (NASDAQ:PRVB) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage currently has $7.00 price target on the stock. According to Zacks, Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics []

In the last trading session, 1.28 million Provention Bio Inc. (NASDAQ:PRVB) shares changed hands as the companys beta touched 2.84. With the companys per share price at $6.79 changed hands at $0.66 or 10.77% during last session, the market valuation stood at $420.10M. PRVBs last price was a discount, traded about -195.29% off its 52-week Why Provention Bio Inc. (NASDAQ: PRVB) Stock Shouldnt Be Sold In 2021 Read More »

Related Stocks: DTM , PRVB , BLUE , JXN , FPAC , FPAC , CND , XPDI , GGPI , DTE , CHK , AXTA , NVT , SNPR , TUEM ,

Analysts expect Provention Bio, Inc. (NASDAQ:PRVB) to post ($0.44) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Provention Bios earnings, with estimates ranging from ($0.45) to ($0.42). Provention Bio reported earnings per share of ($0.58) during the same quarter last year, which would indicate []

Provention Bio, Inc. (PRVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 187.1% in Provention Bio, Inc. (PRVB). While the effectiveness of this highly sought-after metric is questionab

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2021 Results - Earnings Call Transcript

Provention Bio Inc (NASDAQ: PRVB) has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all

RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that m

RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that

RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an upda